Korean All Star Corporationstemporary road map. change happens every day. 19 times a day. Sometimes, at night.
11500KRW
146.23 BKRW
1.49 TKRW
6.31 M
About HANMIPHARM
Sector
CEO
Jong-Yoon Lim
Headquarters
Hwaseong-si
Website
Employees (FY)
2.34 K
Founded
1973
ISIN
KR7128940004
FIGI
BBG000QKWSN4
Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for high blood pressure, hyperlipidemia, reflux esophagitis, and cerebrovascular disease. The company was founded by Lim Sung-Gi on June 15, 1973 and is headquartered in Hwaseong-si, South Korea.
Hanmi Pharmaceutical potential hit 260000 wonA B C area have heavy rejection from 50% of trending area. Current situation have potential hit the support line area; which is 260000 won.
Once price hit support line, make sure check if price is bouncing with high volume to confirm your entering position.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 128940 is 308000 KRW — it has decreased by 2.53% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange HANMIPHARM stocks are traded under the ticker 128940.
HANMIPHARM is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
128940 stock is 3.78% volatile and has beta coefficient of 0.69. Check out the list of the most volatile stocks — is HANMIPHARM there?
One year price forecast for HANMIPHARM has a max estimate of 507000 KRW and a min estimate of 370000 KRW.
128940 earnings for the last quarter are 1.40 K KRW whereas the estimation was 1.45 K KRW which accounts for −3.06% surprise. Estimated earnings for the next quarter are 1.53 K KRW. See more details about HANMIPHARM earnings.
HANMIPHARM revenue for the last quarter amounts to 364.60 B KRW despite the estimated figure of 368.14 B KRW. In the next quarter revenue is expected to reach 400.84 B KRW.
Yes, you can track HANMIPHARM financials in yearly and quarterly reports right on TradingView.
128940 stock has fallen by 1.28% compared to the previous week, the month change is a 6.24% fall, over the last year HANMIPHARM has showed a 0.74% decrease.
128940 net income for the last quarter is 34.39 B KRW, while the quarter before that showed 54.71 B KRW of net income which accounts for −37.13% change. Track more HANMIPHARM financial stats to get the full picture.
Today HANMIPHARM has the market capitalization of 3.77 T, it has decreased by 3.59% over the last week.
Yes, 128940 dividends are paid annually. The last dividend per share was 490.20 KRW. As of today, Dividend Yield (TTM)% is 0.16%. Tracking HANMIPHARM dividends might help you take more informed decisions.
HANMIPHARM dividend yield was 0.14% in 2023, and payout ratio reached 4.17%. The year before the numbers were 0.16% and 7.37% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 128940 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANMIPHARM stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 2.34 K employees. See our rating of the largest employees — is HANMIPHARM on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HANMIPHARM technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HANMIPHARM stock shows the buy signal. See more of HANMIPHARM technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on HANMIPHARM future price: according to them, 128940 price has a max estimate of 507000.00 KRW and a min estimate of 370000.00 KRW. Read a more detailed HANMIPHARM forecast: see what analysts think of HANMIPHARM and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HANMIPHARM EBITDA is 323.34 B KRW, and current EBITDA margin is 21.69%. See more stats in HANMIPHARM financial statements.